Human Gene Therapy (HGT) is the premier, multidisciplinary journal covering all aspects of gene therapy. The Journal publishes important advances in DNA, RNA, cell and immune therapies, validating the latest advances in research and new technologies.
 

Established in 1990, HGT provides a prestigious forum for publishing scientific and clinical research, including ethical, legal, regulatory, social, and commercial issues, which enables the advancement and progress of therapeutic procedures leading to improved patient outcomes, and ultimately, to curing diseases.



 

HGT is published 12 times per year, including sections on Methods (product testing and development) and Clinical Development (regulatory review, toxicology and commercial development). The journal also publishes a wide range of reviews, commentaries and editorials.

Access for members

ESGCT members are entitled to free access to the Journal. Members receive a voucher code on joining or renewing their ESGCT membership.

 

We encourage members to recommend Human Gene Therapy to their library or institution to facilitate collaboration with colleagues.
 

The Journal welcomes your manuscript submissions. All accepted papers are published online ahead of print.
 

Latest Impact Factor: * 5.695
*2020 Journal Citation Reports (Clarivate, 2020)
CiteScore™:  7.7

​

​

​